Anti-TEM7 PLXDC1 Antibody

Tumor endothelial marker 7 (TEM7) was identified through serial analysis of gene expression on endothelial cells isolated from human normal and malignant colorectal tissues. Further experiments verified TEM7 was highly expressed in the endothelium of numerous other cancer types including breast, lung and brain tumors. At least four isoforms of TEM7 are known to exist; these include intracellular, secreted, and membrane-bound forms. A homologous protein, TEM7R (also known as PLXDC2), acts as a binding partner to TEM7 and is also abundantly expressed in the endothelium of malignant colorectal cancer but is absent or rare in normal colon mucosa. High expression of TEM7 is associated with metastasis and poor survival of patients with osteogenic sarcoma.

TEM7 antibody was raised against a 16 amino acid synthetic peptide from near the carboxy terminus of human TEM7. The immunogen is located within the last 50 amino acids of TEM7.

Detected in endothelial cells from colorectal cancer, and in endothelial cells from primary cancers of the lung, liver, pancreas, breast and brain. Not detectable in endothelial cells from normal tissue. Expressed in fibrovascular membrane with increased expression in individuals with proliferative diabetic retinopathy.

TEM7 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. Avoid repeated freeze-thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Isoform 1: Cell membrane; Single-pass type I membrane protein. Cell junction, tight junction. Localized predominantly at the tight junctions of vascular endothelial cells and to a lesser extent at the luminal surface of vascular endothelial cells.